Annual report pursuant to Section 13 and 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.22.0.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Apr. 30, 2017
Dec. 31, 2021
Dec. 31, 2020
Loss Contingencies [Line Items]      
Shares Issued   44,696,923 17,392,343
Research and development   $ 647,302 $ 362,456
Chairman And CEO [Member]      
Loss Contingencies [Line Items]      
Description for employee agreement rate   The employment agreements, as amended, for the Company’s Executive Chairman and CEO each contain a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiary is acquired, equal to 1.75% of the consideration received by the Company. The employment agreement, as amended, for the Company’s General Counsel contains a similar transaction bonus equal to 0.5% of consideration received by the Company  
Employment Agreements [Member]      
Loss Contingencies [Line Items]      
Accrued salary   $ 83,731  
License Agreement [Member] | QSAM Therapeutics Inc [Member]      
Loss Contingencies [Line Items]      
Other Expenses   15,101 97,999
Royalty percentage 4.50%    
Sublicense percentage 5.00%    
Consulting fee   $ 8,500  
Payment for license fees     $ 60,000
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Upon Commercialization [Member]      
Loss Contingencies [Line Items]      
Other Expenses $ 2,000,000    
Shares Issued 500,000    
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member]      
Loss Contingencies [Line Items]      
Other Expenses $ 410,000